Can smarter antibiotic choices curb superbugs in liver disease?
NCT ID NCT05783661
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This trial tests whether using infection surveillance data to guide antibiotic selection can reduce antibiotic resistance in hospitalized cirrhosis patients with bacterial infections. About 198 adults with decompensated cirrhosis and a confirmed or suspected infection will be randomly assigned to receive either standard antibiotics or a regimen tailored based on local surveillance of resistant bacteria. The main goal is to see if the tailored approach lowers the rate of new resistant infections or colonizations within 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- antibiotic regimens guided by epidemiological surveillance
- What this could lead to
- If successful, this approach could help doctors choose antibiotics more effectively, reducing the rise of drug-resistant infections in liver disease patients.
- What could go wrong
- This is a single-center trial with 198 participants, so results may not apply broadly. The surveillance-guided strategy may not outperform standard care and could still lead to resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eva Bonfill
RECRUITINGBarcelona, 08036, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a poop pill protect the liver? trial tests fecal transplants against cirrhosis complications
- New drug CTX-187 takes aim at stubborn bacterial infections
- New bedside test could help doctors fine-tune antibiotics in real time
- New study investigates hidden heart risk in liver patients
- Can the liver heal itself? new study tracks unexpected recovery in cirrhosis patients
- Heart drug may worsen advanced liver disease – major trial underway